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ABSTRACT 
The 2014-2015 Ebola epidemic was the most devastating Ebola outbreak in history,  
killing over 10,000 people. During the outbreak, the WHO led efforts to design the best 
method to test the potential treatments quickly. Randomized controlled trials (RCTs) 
were proposed as the best method, although many experts opposed their use, deeming 
them inappropriate in the context of an epidemic. Despite the long debate, RCTs were 
used to test the available treatments. This paper presents arguments both supporting 
and opposing RCTs, and analyzes a few example RCTs conducted to answer the following 
question: “were RCTs effective at helping researchers fight the epidemic?” This paper 
argues that RCTs were not the best approach for two reasons: the principle of equipoise 
requires that patients are provided available treatments; if RCTs were to be used, they 
should have begun earlier to ensure the validity of the findings. 
 
INTRODUCTION: 
 Ebola virus disease (EVD) is a severe and often fatal illness in humans. EVD first appeared in 
1976 when two outbreaks occurred simultaneously in present-day South Sudan and Democratic 
Republic of Congo (“Ebola virus disease,” 2018). There have been five identified strains of the 
Ebola virus, but three of them (Zaire, Sudan, Bundibugyo) are responsible for the majority of 
cases in humans (Coltart, Lindsey, Ghinai, Johnson, & Heymann, 2017). The Ebola virus is 
introduced into human populations through contact with the blood, secretions, and bodily fluids 
of infected animals such as fruit bats and chimpanzees (“Ebola virus disease,” 2018). From there, 
it spreads between humans through the same mechanism . On March 23, 2014, the WHO's 
regional office in Guinea reported an outbreak of EVD (“Ebola virus disease,” 2018). This 
outbreak spread to nearby counties and primarily affected three West African countries: Guinea, 
Sierra Leone and Liberia. Nigeria was also infected.. It was the most devastating Ebola outbreak 
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in history as 28,646 cases and 11,223 deaths were reported, with the mortality rate in some regions 
as high as 70% (Coltart et al., 2017). 
 During the outbreak, efforts led by the WHO focused on designing the best method to gather 
data about available treatments quickly. Drugs such as Zmapp and vaccines such as ChAd3 
demonstrated effectiveness against Ebola in primates, but they had not yet been tested in humans. 
The gold standard for clinical trials—double-blind Randomized Controlled Trials (RCTs)—was 
proposed, but there were ethical questions regarding its appropriateness in the context of an 
epidemic. The first part of this paper will outline the key arguments given by proponents and 
opponents of RCTs and will also discuss some proposed alternative study designs. The second 
part of the paper will analyze five of the RCTs conducted to assess their safety and efficacy. While 
there were significant arguments for and against RCTs, I argue they were not the best approach 
during the Ebola outbreak because the ethical principle of equipoise required distributing the 
treatments to all patients in this situation, not just those in  the “treatment” group of a RCT. If 
they were to be conducted, RCTs should have started earlier to ensure a large enough sample size 
for the data to be valid and useful. 
ARGUMENTS FOR RANDOMIZED CONTROLLED TRIALS 
Multiple arguments were proposed to justify the need to conduct RCTs, the main one being 
that they ensure the validity of data. In principle, RCTs balance out all the confounding variables 
and ensure comparability between treatment and control groups (Upshur & Fuller 2016). The goal 
is to decrease the likelihood of any observed effect being  the result of variables other than the 
treatment. Lanini et al. (2015) focus on the placebo control group to justify the use of RCTs. The 
authors argue that having a placebo control allows for  clear contrast between the two groups, 
making even minor differences detectable.. In other words, since the only difference expected 
between the two groups is the experimental drug, even small differences would be attributed to 
the drug. Otherwise, the lack of a placebo control group would create uncertainty as to whether 
the effect is due to the experimental treatment or some other factor. Furthermore, the authors 
argue that being able to generate reliable data quickly using RCTs is important because 
researchers will be armed for future outbreaks . Because uncertainty might result from using 
experimental treatments in non-randomized studies, researchers will not be sure that these drugs 
will be effective again in the future. Therefore, RCTs should be conducted to test experimental 
treatments because they provide the most valid results and thus prepare the global community 
for subsequent outbreaks. 
Another reason why researchers believe RCTs should be conducted is that they ensure the 
safety of the patients. The main ethical principle behind this argument is equipoise, which means 
that there is genuine uncertainty among clinical experts over the risks or benefits of an untested 
clinical treatment (Adebamowo et al., 2014). In other words, if healthcare workers are truly 
uncertain about the potential risks associated with the treatment, randomization is the safest 
avenue. Clifford Lane, deputy director for clinical research and special projects at the US National 
Institute of Allergy and Infectious Diseases put it best: "the idea that there is no need for 
controlled trials presupposes that the drugs have zero side effects, that they are efficacious, and 
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that there's no substantial variability from patient to patients [...] I don't think any of that is true" 
(Hayden, 2014). Moreover, Philippe Calain, a researcher for MSF (Doctors Without Borders), 
states that the efficacy of a treatment on animals is not always a good predictor of its effect on 
humans (Calain, 2016). He says this in response to the proposition that one of the experimental 
vaccines shown to be effective in chimpanzees be distributed to all Ebola patients without 
conducting RCTs (“Ethical Considerations for Use of Unregistered Interventions for Ebola Virus 
Disease (EVD),” 2014). This proposition was made during a panel discussion organized by the 
WHO in August 2014. Hence, the potential that the drug might show adverse effects to humans 
as opposed to non-human primates explains the need to conduct RCTs first.  
Additional arguments in favor of RCTs focus on the scarcity of resources in affected countries. 
The first argument is that limited funding and resources demand that treatments be used to 
generate reliable data quickly—any other use would be wasteful. According to Lanini et al. (2015), 
even a small quantity of treatments can be used in RCTs to generate significant data about their 
effectiveness; using them in non-randomized trial would reduce their potential and be wasteful . 
The authors argue that since not everyone can be helped, it makes the most sense to use the few 
treatments available to acquire knowledge which will be more impactful for the present and 
future. In "Evaluating Ebola Therapies - The case for RCTs," the authors take it one step further 
by arguing that since the treatments are limited in quantity, RCTs are not actually depriving 
anyone from the drugs and should instead be used to generate reliable data (Cox, Borio, & Temple, 
2014). The authors argue that the patients in these West African countries would not have had 
access to the treatment anyways, and thus they are not being put in more danger by participating 
in an RCT or being excluded from one. 
Additionally, the limited resources demand that patients be altruistic and accept that the 
burdens and benefits of research will not be distributed equally. Lanini et al. (2015) ask the 
difficult questions very clearly: "How do you distribute treatments that are not produced on a 
mass-scale in non-randomized studies? Who gets it and who doesn't?". The authors make the 
point that even if we wanted to distribute the treatments widely, it is not feasible. This is mainly  
because of the high  cost of treatments and the lack of health infrastructure in affected countries. 
Philippe Calain (2016) attempts to provide an answer by arguing that patients should choose to 
enroll in these trials for the greater good . In other words, patients should accept the risk of being 
placed in a placebo group and forget about their self-interests. There is no need to answer the 
question above, as patients would choose to give up the potential benefits they may obtain from 
an experimental drug for the greater good.  
Calain’s argument assumes that all patients are altruistic and, even in an epidemic, will  act in 
the best interest of society. His argument also outlines the main goal of Randomized Controlled 
Trials (RCTs): to generate robust data that contribute to the advancement of knowledge and 
ultimately benefit future patients (Calain, 2016). The inherent goal of RCTs is not to benefit 
individual patients, but to benefit society as a whole, and more specifically future generations. 
This also suggests that the controversy over the use of RCTs stems from the misunderstanding of 
the goal of these trials  by those who oppose their use. Therefore, scarcity of resources is used as 
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the primary reason to explain that the priority should be to generate data quickly through RCTs, 
and that patients should choose to enroll in these trials for the sake of the greater good. 
ARGUMENTS AGAINST RANDOMIZED CONTROLLED TRIALS 
Multiple arguments have also been put forward to explain why RCTs are not ethical. RCTs, as 
argued by some health care workers, cause mistrust between patients and their healthcare system. 
The article "Randomized controlled trials: practical and ethical issues," was written by authors 
from various countries, including those affected by the Ebola outbreak (Guinea, Nigeria, Liberia). 
In this article, the authors discuss issues that healthcare workers in these countries face. They 
state that because patients are already terrified due to the epidemic and already lack trust in 
healthcare workers, they will be even more distrustful if they know that potential treatments are 
withheld for the purpose of research (Adebamowo et al. 2014). The authors believe that the 
patients would not understand the rationale behind them receiving the “standard of care” 
(nothing or a placebo) when other options are available. Additionally, doctors’ therapeutic 
obligation to treat their patients i conflicts directly with randomization (Calain, 2016). If doctors 
have to enroll their patients into RCTs and some are placed in the placebo group, the doctor-
patient relationship will be compromised because patients cannot be sure that doctors are acting 
in their best interest. Thus, the preservation of patients’ trust and  doctors’ obligation to treat 
justifies the need to avoid RCTs. 
The context of a disease epidemic is also given as a reason for why RCTs are inappropriate, 
since they are neither ethically acceptable nor feasible. According to Adebamowo et al. (2014), the 
concept of equipoise, which was discussed earlier as justification for RCTs, breaks down "when 
conventional care offers little benefit and mortality is extremely high." The Ebola outbreak was 
rapidly claiming people's lives, with mortality rates as high as 70% in some regions (Adebamowo 
et al. 2014). In other words, because conventional care was ineffective, any experimental 
treatment would most likely yield more benefits than harm and should therefore be used. Jeremy 
Farrar, head of the Wellcome Trust and an infectious disease researcher, argues that RCTs are 
just as problematic for sick healthcare workers when he asks: "if you were there tomorrow and 
you were a healthcare worker, would you be willing to be in a control arm when the next three 
months you will be looking after patients with Ebola?" (Cohen & Kupferschmidt, 2014). This 
implies that local healthcare workers would be just as likely to take the risk. Hence, RCTs are not 
ethically acceptable to both patients and workers because high mortality rates minimize the risk 
of taking an experimental treatment. 
Additionally, RCTs are not feasible in the context of an epidemic. First of all, when patients are 
terrified due to an Ebola outbreak, they cannot offer truly voluntary informed consent 
(Adebamowo et al. 2014). This means that patients would be too distracted by their deteriorating 
health and the conditions around them to make an informed decision regarding the trials. 
Moreover, it might not be possible to control conditions during an epidemic because the trials 
would be conducted in areas where healthcare systems are breaking down and fear has been 
instilled in the communities (Adebamowo et al., 2014; Hayden, 2014; Kanapathipillai et al., 2014). 
This argument is significant since one of the reasons why RCTs are considered superior is because 
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they balance confounding variables and ensure that the only difference between the two groups is 
the experimental treatments. However, if the trials are conducted in settings were healthcare 
systems are broken and people are scared, anxious and distrustful of health facilities, it may not 
be possible to control for all the factors that could affect the results. 
The final argument against RCTs directly attacks the claim that they produce more reliable and 
valid data. In their article "Randomized Controlled Trials in the West African Ebola virus 
outbreak," Ross Upshur and Jonathan Fuller (2016) argue that it is impossible to balance out all 
the confounding variables. They state that "all studies fall short of the guarantee of pristine group 
comparability and that this ideal is not required". They believe that the absence of selection bias 
is necessary when a study is only looking for a small outcome, whereas investigators who are 
designing Ebola treatments want to see large treatment effects. They argue that if a drug is 
effective, it should have a drastic effect on patients' survival rate, which would be noticeable even 
in non-randomized studies, rendering RCTs unnecessary. This is in contrast to Lanini et al. (2015) 
article which argues that RCTs are necessary because they will enable researchers to detect small 
effects. The difference in opinion comes from whether researchers are looking for small or large 
outcomes; Upshur and Fuller would argue that large outcomes are needed when the mortality rate 
is so high. They end their article by stating that there is no gold standard, as the best design 
depends on the purpose and context, which is also a point made in other articles (Adebamowo et 
al. 2014; Hayden 2014; Upshur and Fuller 2016).  
ALTERNATIVE DESIGNS 
Most of the articles that argue against RCTs propose alternative approaches, two of which will 
be discussed. The most emphasized design was the adaptive RCT. In this type of study, the trial is 
modified as data is generated (Calain, 2016; Lanini et al., 2015). For example, if a large number 
of people die in the control group compared to the experimental group during the first few weeks 
of the trial, the trial would be modified so that more people in the control group would receive the 
drug. In other words, the likelihood that the trial will end depends on the mortality rate in the 
control group (Adebamowo et al. 2014). This would minimize the number of people in the control 
group who do not receive the treatment. The reasoning behind this design is that if a treatment is 
extraordinarily effective, it would be evident early on and the trial would end early so that 
everyone can receive the new treatment (Lanini et al. 2015). Alternatively, if the drug is not very 
effective, the difference between the two groups will probably not be significant, and the trial 
would continue as planned. An adaptive design preserves the scientific superiority of RCTs while 
ensuring that most people receive the treatment on time. 
Another alternative is the stepped wedge design, which ensures that all people receive vaccines, 
but at different time periods. In this design, as shown in figure 1, participants are randomly 
assigned to different groups which receive the vaccine at one of several time periods 
(Kanapathipillai et al. 2014). Outcomes in each group are measured at each point where the next 
group receives the vaccine (Kanapathipillai et al. 2014). This allows researchers to gather data 
sequentially and to compare the results of groups at different time points. According to virologist 
Barney Graham, such a design would be more ethically acceptable to patients because everyone 
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eventually receives the treatment (Cohen & Kupferschmidt, 2014). Therefore, similar to the 
adaptive design, such a technique would decrease the likelihood that a large number of people do 
not receive the treatment and is thus more ethically acceptable than traditional RCTs.
 
Figure 1. Stepped-wedge study design (Kanapathipillai et al. 2014) 
WAS THE APPROACH EFFECTIVE? 
Despite all the proposed arguments against RCTs, multiple RCTs were conducted in West 
Africa and abroad for the candidate drugs and vaccines that were available in 2014-2015. Three 
of these treatments will be discussed: the triple monoclonal antibody cocktail Zmapp, the 
chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3) and the recombinant 
vesicular stomatitis virus vaccine (rVSV). Five randomized studies conducted between 2014 and 
2015 will be analyzed to argue that RCTs were not the best method to effectively address the 2014-
2015 epidemic because the principle of equipoise requires distributing the drugs to all patients, 
not just those enrolled in the treatment arm. Alternatively, if they were to be conducted, RCTs 
should have been started earlier to ensure a large enough sample size for the data to be valid and 
useful. 
The first reason why RCTs were not the best approach is that these studies all showed that the 
experimental treatments were safe, immunogenic and/or partially effective. A study conducted 
between September and November 2014 tested the safety and immunogenicity of ChAd3 on 60 
adult volunteers in Oxford, United Kingdom (Ewer et al., 2016). The participants received one 
injection of the vaccine at three different doses. The investigators did not identify any safety 
concerns and determined that the vaccine was immunogenic (may help the body mount an 
immune response against the Ebola virus) at the three different doses (Ewer et al., 2016). Another 
study conducted between October 2014 and February 2015 tested the safety and immunogenicity 
of ChAd3 on 91 participants in Mali and 20 in the US (Tapia et al., 2016). The participants received 
either different doses of the vaccine or a placebo. Again, the vaccine was safe and the investigators 
determined the dose of the vaccine that could be used in ring-vaccinations to provide "high-level 
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protection" (Tapia et al., 2016). Another study conducted between October 2014 and June 2015 
tested the safety and immunogenicity of ChAd3 on 120 participants in Switzerland (De Santis et 
al., 2016). They also concluded that the vaccine was safe, although there were mild to moderate 
adverse effects, including fatigue and headache. The vaccine was shown to be immunogenic even 
after 6 months and the investigators recommended its use in phase 2 and 3 trials. 
Another study conducted between February and April 2015 tested the safety and 
immunogenicity of ChAd3 and rVSV on 1500 participants in Liberia (Kennedy et al., 2017). One 
month after treatment, the vaccine had elicited an immune response which was sustained over 12 
months and no safety concerns were identified (Kennedy et al., 2017). Finally, another study was 
conducted beginning March 2015 to determine the effectiveness of ZMapp in a total 72 patients 
in Liberia, Sierra Leone, Guinea, and the United States. Patients received either ZMapp and the 
standard of care or the standard of care alone. In the control group, 37% of people died compared 
to 22% in the experimental group, which meant that Zmapp was 91.2% superior to the standard 
of care alone, although it did not meet the 97.5% threshold to qualify as effective (The PREVAIL 
II Writing Group, 2016). All five studies had one thing in common: they showed that the 
treatments were safe and potentially effective. The principle of equipoise requires balancing the 
risks and benefits of experimental treatments compared to conventional care (Adebamowo et al. 
2014). As mentioned earlier, the mortality rate was as high as 70% in some regions following 
conventional care measures. Hence, the high mortality rate with conventional care illustrates that 
this epidemic was time-sensitive, as it was rapidly killing patients. The results of the study suggest 
that because of the need to act quickly, the risk was worth taking as the experimental treatments 
were unlikely to be riskier than the conventional care. The principle of equipoise would therefore 
dictate that the drugs be made available to all patients. One can thus argue that they should have 
been distributed in non-randomized studies to potentially reduce the number of deaths. 
Another reason why RCTs were not the best approach is the fact that they were so controversial 
and led to long debates which delayed intervention. While the epidemic was declared in March 
2014, the first RCT began in September 2014 as a result of the debate over the best design to use 
(Ewer et al., 2016). This delay weakened the trial because there were few available patients for 
enrollment after it formally started. Two studies addressed this issue. The RCT conducted in 
Liberia was initially planned to be both phase 3 (which would involve Ebola patients to determine 
the efficacy of the experimental therapies) and phase 2 trials (to determine safety, by using healthy 
subjects) (Kennedy et al., 2017). However, because of the decline in new Ebola cases, investigators 
were unable to enroll enough Ebola patients, and could only enroll healthy patients and assess 
safety and immunogenicity in a phase 2 trial (Kennedy et al., 2017). The study was conducted in 
2015, and investigators were unable to test the vaccines on enough patients to determine its 
effectiveness. Similarly, the ZMapp study described above also needed to start the experiments 
early since it had been proven to be effective in non-human primates in the 5-day window after 
infection (The PREVAIL II Writing Group, 2016). In reality, it was difficult to find and recruit 
patients in the midst of the epidemic, and the patients ultimately enrolled were more than one 
week past their date of infection. 
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For those people enrolled in the ZMapp trial, those who died in the experimental group died 
before receiving their second of three programmed ZMapp injections (The PREVAIL II Writing 
Group, 2016). Patients already had the disease for quite some time before enrolling in the trial, 
which implies that the trial did not test the full potential of this drug. The fact that they did not 
even receive two of the programmed injections and ZMapp was still 91.5% superior to the 
standard of care shows that it could be more effective. Finally, the authors attribute their small 
sample size to the decline in cases (The PREVAIL II Writing Group, 2016). A larger sample size 
may have highlighted the effectiveness of ZMapp to a greater extent. This again shows that the 
delay in starting the intervention were due to the debates regarding the most appropriate study 
design, leading to a small sample size for the trials and thus an ineffective assessment of the 
treatments. While this may suggest that RCTs would have been beneficial if they had started early, 
it actually highlights why they were problematic: the controversy that arose over their use delayed 
intervention, which was detrimental because the ability of researchers to generate valid data 
regarding the treatments required an earlier start. 
Finally, RCTs were not the best approach to address the epidemic because the typical process 
of conducting drug trials ensured that patients would not have acquired the treatments in a timely 
manner. Even if the trials had started on time, it might have still taken too long before the 
treatments were offered to patients. This is first due to the need to conduct safety trials. Four of 
the studies described earlier were safety and immunogenicity trials. Because Phase 1 trials are 
required before conducting phase 2 or phase 3 trials, this would have further delayed the date of 
treatment. Additionally, scientific data must be repeatable. The safety trials for the ChAd3 vaccine 
were conducted in the US, the UK, Switzerland and Mali, and they all confirmed that the vaccine 
was safe, which was necessary to make sure that the data is reliable. Even if the trials had started 
earlier, conducting all these safety trials in different locations would have also delayed the 
intervention. It would have been more efficient to conduct the safety trials in the areas affected 
first, and move on to efficacy trials. Finally, the trials themselves lasted between 2 and 12 months. 
This is relatively long considering that Ebola patients were dying rapidly. Because it would have 
taken so long to generate significant data, the principle of equipoise again requires that the 
treatments be made widely available. The principle of equipoise insists that as long as there is 
uncertainty over the risks and benefits of the experimental treatments, safety trials must be 
conducted and valid data must be generated through randomization. However, because of the 
need to act quickly and the high mortality rates, the time it would have taken to generate data in 
order to help patients provides additional evidence for the argument that RCTs were not the best 
approach. 
 
CONCLUSION: 
As this paper has shown, there were valid arguments on both sides of the debate for the 
appropriateness of RCTs during the 2014-2015 Ebola epidemic. On one hand, proponents of RCTs 
focused on the need to generate robust data, the safety of patients, and the benefit to society as a 
whole. On the other hand, opponents of RCTs focused on high mortality rate, the need to preserve 
patient-doctor trust, and the benefit to individual patients. One interesting dilemma that arose 
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from these arguments is whether the priority of researchers lies in  observing small improvements 
or more obvious ones through the use of experimental treatments. Some proponents of RCTs 
argued that this type of experimental design detects small differences between the two groups, 
but opponents argued that RCTs are not necessary because as long as the drug is significantly 
effective, removing all the confounding variables is not required. 
A close look at five RCTs conducted during and after the outbreak led to the conclusion that 
RCTs were not the best approach because the principle of equipoise required that treatments be 
made available to patients. Alternatively, RCTs should have been started earlier to ensure a high 
enough sample size for the data to be valid. All of the studies found that the experimental 
treatments were safe and immunogenic. Thus, the treatments should have been distributed to 
patients because the studies showed that the patients would not have been in  greater risk than 
with conventional care. Additionally, the delay in interventions, due to the debates over the 
appropriateness of RCTs, made it more difficult for researchers to gather data because cases began 
to decline. Finally, the actual process of conducting clinical trials was another roadblock because 
it ensured that the patients would not be provided with the treatments on time. Ultimately, the 
findings from these and subsequent RCTs add to the knowledge on treatments for EVD and will 
be beneficial to future patients. The next epidemic will be less challenging  because there will be 
some knowledge on the safety and potential efficacy of these treatments, which means that 
healthcare workers will be better armed. This fact is not surprising because, as mentioned above, 
the goal of RCTs is not to help individual patients but to generate knowledge that will be beneficial 
to society as a whole, and especially future generations. 
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